Coya Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Arun Swaminathan
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5850 San Felipe Street Houston TX United States of America 77057
- IPO Date
- Dec 29, 2022
- CIK
- 0001835022
- Website
- coyatherapeutics.com
- Similar Companies
- Business
- Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing proprietary therapies that enhance the function of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its core products and services include multi-modality Treg therapies, specifically Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company’s lead product candidates, the 300 Series, include COYA 301 and COYA 302, with COYA 302 being an investigational biologic combination therapy composed of low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig intended for subcutaneous administration. This investigational therapy is designed to modulate immune responses by enhancing Treg function and suppressing inflammation caused by activated monocytes and macrophages. Coya targets therapeutic areas including neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson’s disease, as well as autoimmune and metabolic diseases. The company operates primarily out of its Houston, Texas headquarters and pursues global clinical research and development initiatives. In recent developments, Coya Therapeutics has secured FDA acceptance of an Investigational New Drug (IND) application for COYA 302 for the treatment of ALS and has launched the ALSTARS trial, a Phase 2 clinical study assessing the efficacy and safety of COYA 302 in ALS patients. The company expanded the therapeutic indications for COYA 302 to include frontotemporal dementia and Parkinson’s disease, with IND submissions anticipated for FTD in late 2025 and planned preclinical studies for PD. Coya has also expanded its research collaboration with the Houston Methodist Research Institute to advance proprietary Treg exosome technology toward clinical studies and validate biomarkers for multiple neurodegenerative disorders. Strategically, Coya has forged a commercialization partnership with Dr. Reddy’s Laboratories for COYA 302, which includes milestone payments and leverages Dr. Reddy’s global pharmaceutical infrastructure. Financially, Coya closed a $23 million upsized public offering in 2025, extending its cash runway into the second half of 2027. The company continues to expand its intellectual property portfolio and pipeline with novel combination therapies aimed at inflammatory and neurodegenerative conditions.
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of “Moderate Buy” from Brokerages
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
Coya Therapeutics (COYA) to Release Quarterly Earnings on Tuesday
Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?
Coya Therapeutics Details ALS Combo Immunotherapy Plan, Highlights Early Biomarker Signals in Webinar
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
Coya Therapeutics Announces $11.1 Million Private Placement
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders